Similarly, patients with ALK-rearranged NSCLC CNS metastasis have a dramatic response to ALK-TKI treatment with RRs of 36–72% (progression-free survival [PFS] 5.7–13.2 months) [22]. This evidence concerns the gene ALK and non-small cell lung carcinoma.